Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acolbifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 20/20 | 1.00 |
| ▸ | ESR2 known ✓ | Q92731 | 16/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acolbifene SCHEMBL29351361 | 1.00 | ESR1 (1.00) | ESR1ESR2 | |
| Acolbifene SCHEMBL406183 | 1.00 | ESR1 (1.00) | ESR1ESR2 | |
| Acolbifene SCHEMBL4447852 | 1.00 | ESR1 (1.00) | ESR1ESR2 | |
| Acolbifene SCHEMBL9979094 | 0.99 | ESR1 (0.98) | ESR1ESR2 | |
| SCHEMBL15019602 | 0.99 | ESR1 (0.98) | ESR1ESR2 | |
| SCHEMBL7054458 | 0.95 | ESR1 (0.91) | ESR1ESR2 | |
| Acolbifene SCHEMBL28088521 | 0.93 | ESR1 (0.87) | ESR1ESR2 | |
| SCHEMBL4804921 | 0.93 | ESR1 (0.87) | ESR1ESR2 | |
| SCHEMBL14856500 | 0.91 | ESR1 (0.87) | ESR1ESR2 | |
| SCHEMBL7056486 | 0.91 | ESR1 (0.91) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3682880-A1 | TREATMENT OF HOT FLUSHES, VASOMOTOR SYMPTOMS, AND NIGHT SWEATS WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | Endorecherche, Inc. (CA) | 2020-07-22 | — | — | EP | disclosed |
| US-20170290847-A1 | TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM | ENDORECHERCHE, INC. | 2017-10-12 | — | — | US | disclosed |
| US-20170290847-A1 | TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM | ENDORECHERCHE, INC. | 2017-10-12 | — | — | US | disclosed |
| EP-1104414-B1 | ENANTIOSELECTIVE SYNTHESIS | SCHERING CORP (US) | 2003-02-12 | — | — | EP | disclosed |
| US-6262270-B1 | HYDROXYPHENYLACETOPHENONE DERIVATIVE IS REACTED WITH N-ETHOXYBENZYL PIPERIDINE COMPOUND IN PRESENCE OF PIPERIDINE AND HINDERED AMINE BASE AND ALKANOL TO PRODUCE PURE ANTIESTROGEN COMPOUND | SCHERING CORPORATION | 2001-07-17 | — | — | US | disclosed |
| EP-1104414-A1 | ENANTIOSELECTIVE SYNTHESIS | SCHERING CORPORATION (US) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009493-A1 | ENANTIOSELECTIVE SYNTHESIS | SCHERING CORPORATION (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290847-A1 | TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM | SHBG, CYP19A1, AR | ESR1 52/4885ESR2 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.